AC免疫SA
US ˙ NasdaqGM ˙ CH0329023102

SecurityACIU / AC Immune SA
InstitutionBarclays Plc
Latest Disclosed Ownership2,701 shares
Latest Disclosed Value $ 8,481
Barclays Plc reports 48.94% decrease in ownership of ACIU / AC Immune SA

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 2,701 shares of AC Immune SA (US:ACIU) valued at $8,481 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 5,290 shares of AC Immune SA. This represents a change in shares of -48.94% during the quarter. The current value of the position is $6,482 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F AC IMMUNE COM H00263105 2,701 -2,589 -48.94 8 -46.67 0.0000
2026-03-31 2025-09-30 13F/A-3 AC IMMUNE COM H00263105 5,290 -2,617 -33.10 15 -6.25 0.0000
2026-03-19 2025-09-30 13F/A-2 AC IMMUNE COM H00263105 490 -7,417 2 0.0000
2025-11-12 2025-09-30 13F AC IMMUNE COM H00263105 5,290 -2,617 15 0.0000
2026-02-27 2025-06-30 13F/A-2 AC IMMUNE COM H00263105 7,907 498 6.72 16 23.08 0.0000
2025-08-14 2025-06-30 13F/A-1 AC IMMUNE COM H00263105 7,907 498 0 0.0000
2025-08-13 2025-06-30 13F AC IMMUNE COM H00263105 7,907 498 0 0.0000
2026-03-17 2025-03-31 13F/A-1 AC IMMUNE COM H00263105 7,409 1,537 26.18 14 -13.33 0.0000
2025-05-15 2025-03-31 13F AC IMMUNE COM H00263105 7,409 1,537 0 0.0000
2026-03-19 2024-12-31 13F/A-1 AC IMMUNE COM H00263105 5,872 5,382 1,098.37 16 1,400.00 0.0000
2025-02-13 2024-12-31 13F AC IMMUNE COM H00263105 5,872 5,382 0 0.0000
2026-03-31 2024-09-30 13F/A-2 AC IMMUNE COM H00263105 490 490 2 0.0000
2024-11-19 2024-09-30 13F/A-1 AC IMMUNE COM H00263105 490 490 0 0.0000
2024-11-15 2024-09-30 13F AC IMMUNE COM H00263105 490 490 0 0.0000
2022-02-23 2021-12-31 13F/A-1 AC IMMUNE COM H00263105 0 -7,068 -100.00 0 -100.00
2022-02-14 2021-12-31 13F AC IMMUNE COM H00263105 0 -7,068 0
2021-11-09 2021-09-30 13F AC IMMUNE COM H00263105 7,068 6,950 5,889.83 48 4,700.00 0.0000
2021-08-13 2021-06-30 13F AC IMMUNE COM H00263105 118 -274 -69.90 1 -66.67 0.0000
2021-05-13 2021-03-31 13F AC IMMUNE COM H00263105 392 286 269.81 3 200.00 0.0000
2021-02-11 2020-12-31 13F AC IMMUNE COM H00263105 106 0 0.00 1 0.00 0.0000
2020-11-12 2020-09-30 13F AC IMMUNE COM H00263105 106 0 0.00 1 0.00 0.0000
2020-08-12 2020-06-30 13F AC IMMUNE COM H00263105 106 106 1 0.0000
2020-05-13 2020-03-31 13F AC IMMUNE COM H00263105 0 -134 -100.00 0 -100.00
2020-02-10 2019-12-31 13F AC IMMUNE COM H00263105 134 -350 -72.31 1 -50.00 0.0000
2019-11-15 2019-09-30 13F/A-1 AC IMMUNE COM H00263105 484 0 0.00 2 -33.33 0.0000
2019-11-14 2019-09-30 13F AC IMMUNE COM H00263105 484 0 2 0.4624
2019-08-14 2019-06-30 13F AC IMMUNE COM H00263105 484 484 3 0.0000
2019-05-15 2019-03-31 13F AC IMMUNE COM H00263105 0 -6,378 -100.00 0 -100.00
2019-02-14 2018-12-31 13F AC IMMUNE COM H00263105 6,378 5,606 726.17 61 916.67 0.0000
2018-11-14 2018-09-30 13F AC IMMUNE COM H00263105 772 772 6 0.0000
2018-08-14 2018-06-30 13F AC IMMUNE COM H00263105 0 -5,500 -100.00 0 -100.00
2018-05-15 2018-03-31 13F AC IMMUNE COM H00263105 5,500 -4,700 -46.08 57 -56.49 0.0000
2018-02-14 2017-12-31 13F AC IMMUNE COM H00263105 10,200 10,200 131 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.